Menu
11/03/2014
Blood Test Identifies Those At-Risk Of Alzeimer's Within Three Years
Researchers have discovered and validated a blood test that can predict with greater than 90 percent accuracy if a healthy person will develop mild cognitive impairment or Alzheimer's disease within three years.
Described in the April issue of Nature Medicine, the study heralds the potential for developing treatment strategies for Alzheimer's at an earlier stage, when therapy would be more effective at slowing or preventing onset of symptoms.
The test identifies 10 lipids, or fats, in the blood that predict disease onset. It could be ready for use in clinical studies in as few as two years and, researchers say, other diagnostic uses are possible.
"Our novel blood test offers the potential to identify people at risk for progressive cognitive decline and can change how patients, their families and treating physicians plan for and manage the disorder," said the study's corresponding author Howard J. Federoff, MD, PhD, professor of neurology and executive vice president for health sciences at Georgetown University Medical Center.
There is no cure or effective treatment for Alzheimer's. Worldwide, about 35.6 million individuals have the disease and, according to the World Health Organization, the number will double every 20 years to 115.4 million people with Alzheimer’s by 2050.
Mr Federoff explained there have been many efforts to develop drugs to slow or reverse the progression of Alzheimer’s disease, but all of them have failed. He says one reason may be the drugs were evaluated too late in the disease process.
"The preclinical state of the disease offers a window of opportunity for timely disease-modifying intervention," Mr Federoff said. "Biomarkers such as ours that define this asymptomatic period are critical for successful development and application of these therapeutics."
The study included 525 healthy participants aged 70 and older who gave blood samples upon enrolling and at various points in the study. Over the course of the five-year study, 74 participants met the criteria for either mild Alzheimer’s disease (AD) or a condition known as amnestic mild cognitive impairment (aMCI), in which memory loss is prominent. Of these, 46 were diagnosed upon enrollment and 28 developed aMCI or mild AD during the study.
(CVS/CD)
Described in the April issue of Nature Medicine, the study heralds the potential for developing treatment strategies for Alzheimer's at an earlier stage, when therapy would be more effective at slowing or preventing onset of symptoms.
The test identifies 10 lipids, or fats, in the blood that predict disease onset. It could be ready for use in clinical studies in as few as two years and, researchers say, other diagnostic uses are possible.
"Our novel blood test offers the potential to identify people at risk for progressive cognitive decline and can change how patients, their families and treating physicians plan for and manage the disorder," said the study's corresponding author Howard J. Federoff, MD, PhD, professor of neurology and executive vice president for health sciences at Georgetown University Medical Center.
There is no cure or effective treatment for Alzheimer's. Worldwide, about 35.6 million individuals have the disease and, according to the World Health Organization, the number will double every 20 years to 115.4 million people with Alzheimer’s by 2050.
Mr Federoff explained there have been many efforts to develop drugs to slow or reverse the progression of Alzheimer’s disease, but all of them have failed. He says one reason may be the drugs were evaluated too late in the disease process.
"The preclinical state of the disease offers a window of opportunity for timely disease-modifying intervention," Mr Federoff said. "Biomarkers such as ours that define this asymptomatic period are critical for successful development and application of these therapeutics."
The study included 525 healthy participants aged 70 and older who gave blood samples upon enrolling and at various points in the study. Over the course of the five-year study, 74 participants met the criteria for either mild Alzheimer’s disease (AD) or a condition known as amnestic mild cognitive impairment (aMCI), in which memory loss is prominent. Of these, 46 were diagnosed upon enrollment and 28 developed aMCI or mild AD during the study.
(CVS/CD)
Related UK National News Stories
Click here for the latest headlines.
21 July 2005
Blood donors warned over possible vCJD carriage
Around 100 people who donated blood to three people who subsequently developed vCJD, have been warned that they may have a greater chance of carrying the agent that causes the disease.
Blood donors warned over possible vCJD carriage
Around 100 people who donated blood to three people who subsequently developed vCJD, have been warned that they may have a greater chance of carrying the agent that causes the disease.
06 December 2006
Feline Alzheimer's risk for cats
Ageing cats can develop a feline form of Alzheimer’s disease, a new study has claimed. Researchers at the Universities of Edinburgh, St Andrews, Bristol and California identified a key protein which can build up in the nerve cells of a cat's brain and cause mental deterioration.
Feline Alzheimer's risk for cats
Ageing cats can develop a feline form of Alzheimer’s disease, a new study has claimed. Researchers at the Universities of Edinburgh, St Andrews, Bristol and California identified a key protein which can build up in the nerve cells of a cat's brain and cause mental deterioration.
15 February 2011
Obesity Is Heart Disease Killer In Its Own Right, Study Shows
Obesity is a killer in its own right, irrespective of other biological or social risk factors traditionally associated with coronary heart disease, suggests research published online in Heart.
Obesity Is Heart Disease Killer In Its Own Right, Study Shows
Obesity is a killer in its own right, irrespective of other biological or social risk factors traditionally associated with coronary heart disease, suggests research published online in Heart.
29 May 2009
Widespread Use Of Aspirin Slammed
A new study in The Lancet medical journal has found that healthy people who take aspirin reduced their already small risk of heart attack or stroke by just 12%. However, the small risk of internal bleeding increased by a third.
Widespread Use Of Aspirin Slammed
A new study in The Lancet medical journal has found that healthy people who take aspirin reduced their already small risk of heart attack or stroke by just 12%. However, the small risk of internal bleeding increased by a third.
23 March 2006
Male smokers 'more likely to be impotent'
Men who smoke more than a pack of cigarettes per day are 40% more likely to be impotent than those who do not, according to new research. Research conducted as part of the Australian Study of Health and Relationships questioned over 8,000 men aged between 16 and 59 on erection problems.
Male smokers 'more likely to be impotent'
Men who smoke more than a pack of cigarettes per day are 40% more likely to be impotent than those who do not, according to new research. Research conducted as part of the Australian Study of Health and Relationships questioned over 8,000 men aged between 16 and 59 on erection problems.
-
Northern Ireland WeatherToday:After a dry start this morning rain will spread from the northwest across all parts. This afternoon will be dull with some patchy rain and drizzle. Becoming much milder through the afternoon. Maximum temperature 11 °C.Tonight:A cloudy evening and night with a little light rain or drizzle, perhaps some clear periods developing along the east coast. A very mild night everywhere. Minimum temperature 10 °C.
